Skip to main
EPRX
EPRX logo

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals Inc. benefits from a favorable competitive landscape for its product EP-104, particularly following the CLDX announcement, which mitigates competitive pressures in the eosinophilic esophagitis (EoE) treatment space. The promising outcomes demonstrated in the Phase 1b/2a portion of the RESOLVE trial indicate that the drug has shown durability and sustained treatment outcomes, with active drug release observed nine months after administration. Additionally, a successful Phase 2b trial could lead to a streamlined Phase 3 trial, enhancing the pathway toward regulatory approval and potentially solidifying Eupraxia's market position in addressing unmet medical needs.

Bears say

Eupraxia Pharmaceuticals faces significant risks related to potential cross-border supply chain disruptions and tariffs, which could adversely affect its operational efficiency and cost structure. The company’s reliance on its proprietary Diffusphere technology for drug delivery may not sufficiently mitigate these risks, jeopardizing its competitive advantage in a challenging market. Furthermore, the financial implications of tariffs and supply chain volatility could strain the company's resources, further impacting its development and commercialization efforts.

EPRX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 2 analysts, EPRX has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.